Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
<h4>Objective</h4>To describe the profile of patients with multiple sclerosis (MS) treated with fingolimod in Spain and to assess the effectiveness and safety of fingolimod after 4 years of inclusion in the Spanish Gilenya Registry.<h4>Methods</h4>An observational, retrospect...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/07987836f8b74fd78ad563e5d9b47c6e |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:07987836f8b74fd78ad563e5d9b47c6e |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:07987836f8b74fd78ad563e5d9b47c6e2021-12-02T20:19:15ZFour-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.1932-620310.1371/journal.pone.0258437https://doaj.org/article/07987836f8b74fd78ad563e5d9b47c6e2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0258437https://doaj.org/toc/1932-6203<h4>Objective</h4>To describe the profile of patients with multiple sclerosis (MS) treated with fingolimod in Spain and to assess the effectiveness and safety of fingolimod after 4 years of inclusion in the Spanish Gilenya Registry.<h4>Methods</h4>An observational, retrospective/prospective, multicenter case registry, including all patients with relapsing-remitting MS (RRMS) starting treatment with fingolimod in 43 centers in Spain. Analyses were performed in the overall population and in subgroups according to prior disease-modifying therapy (DMT): glatiramer acetate/interferon beta-1 (BRACE), natalizumab, other treatment, or naïve.<h4>Results</h4>Six hundred and sixty-six evaluable patients were included (91.1% previously treated with at least one DMT). The mean annualized relapse rate (ARR) prior to fingolimod was 1.12, and the mean EDSS at fingolimod initiation was 3.03. Fingolimod reduced the ARR by 71.4%, 75%, 75.5%, and 80.3%, after 1, 2, 3 and 4 years, respectively (p<0.001). This significant reduction in the ARR continued to be observed in all subgroups. After 4 years, the EDSS showed a minimal deterioration, with the EDSS scores from year 1 to year 4 remaining mostly stable. The percentage of patients without T1 Gd+ lesions progressively increased from 45.6% during the year prior to fingolimod initiation to 88.2% at year 4. The proportion of patients free from new/enlarged T2 lesions after 4 years of fingolimod treatment was 80.3%. This trend in both radiological measures was also observed in the subgroups. Adverse events (AEs) were experienced by up to 41.6% of patients (most commonly: lymphopenia [12.5%] and urinary tract infection [3.7%]). Most AEs were mild in severity, 3.6% of patients had serious AEs.<h4>Conclusions</h4>The patient profile was similar to other observational studies. The results obtained from the long-term use of fingolimod showed that it was effective, regardless of prior DMT, and it had adequate safety results, with a positive benefit-risk balance.J E Meca-LallanaC Oreja-GuevaraD MuñozJ OlascoagaA PatoL Ramió-TorrentàV Meca-LallanaM A HernándezM E MarzoJ C Álvarez-CermeñoA Rodríguez-AntigüedadX MontalbánO FernándezSpanish GILENYA Registry InvestigatorsPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 10, p e0258437 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q J E Meca-Lallana C Oreja-Guevara D Muñoz J Olascoaga A Pato L Ramió-Torrentà V Meca-Lallana M A Hernández M E Marzo J C Álvarez-Cermeño A Rodríguez-Antigüedad X Montalbán O Fernández Spanish GILENYA Registry Investigators Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry. |
| description |
<h4>Objective</h4>To describe the profile of patients with multiple sclerosis (MS) treated with fingolimod in Spain and to assess the effectiveness and safety of fingolimod after 4 years of inclusion in the Spanish Gilenya Registry.<h4>Methods</h4>An observational, retrospective/prospective, multicenter case registry, including all patients with relapsing-remitting MS (RRMS) starting treatment with fingolimod in 43 centers in Spain. Analyses were performed in the overall population and in subgroups according to prior disease-modifying therapy (DMT): glatiramer acetate/interferon beta-1 (BRACE), natalizumab, other treatment, or naïve.<h4>Results</h4>Six hundred and sixty-six evaluable patients were included (91.1% previously treated with at least one DMT). The mean annualized relapse rate (ARR) prior to fingolimod was 1.12, and the mean EDSS at fingolimod initiation was 3.03. Fingolimod reduced the ARR by 71.4%, 75%, 75.5%, and 80.3%, after 1, 2, 3 and 4 years, respectively (p<0.001). This significant reduction in the ARR continued to be observed in all subgroups. After 4 years, the EDSS showed a minimal deterioration, with the EDSS scores from year 1 to year 4 remaining mostly stable. The percentage of patients without T1 Gd+ lesions progressively increased from 45.6% during the year prior to fingolimod initiation to 88.2% at year 4. The proportion of patients free from new/enlarged T2 lesions after 4 years of fingolimod treatment was 80.3%. This trend in both radiological measures was also observed in the subgroups. Adverse events (AEs) were experienced by up to 41.6% of patients (most commonly: lymphopenia [12.5%] and urinary tract infection [3.7%]). Most AEs were mild in severity, 3.6% of patients had serious AEs.<h4>Conclusions</h4>The patient profile was similar to other observational studies. The results obtained from the long-term use of fingolimod showed that it was effective, regardless of prior DMT, and it had adequate safety results, with a positive benefit-risk balance. |
| format |
article |
| author |
J E Meca-Lallana C Oreja-Guevara D Muñoz J Olascoaga A Pato L Ramió-Torrentà V Meca-Lallana M A Hernández M E Marzo J C Álvarez-Cermeño A Rodríguez-Antigüedad X Montalbán O Fernández Spanish GILENYA Registry Investigators |
| author_facet |
J E Meca-Lallana C Oreja-Guevara D Muñoz J Olascoaga A Pato L Ramió-Torrentà V Meca-Lallana M A Hernández M E Marzo J C Álvarez-Cermeño A Rodríguez-Antigüedad X Montalbán O Fernández Spanish GILENYA Registry Investigators |
| author_sort |
J E Meca-Lallana |
| title |
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry. |
| title_short |
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry. |
| title_full |
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry. |
| title_fullStr |
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry. |
| title_full_unstemmed |
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry. |
| title_sort |
four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: the spanish gilenya registry. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2021 |
| url |
https://doaj.org/article/07987836f8b74fd78ad563e5d9b47c6e |
| work_keys_str_mv |
AT jemecalallana fouryearsafetyandeffectivenessdatafrompatientswithmultiplesclerosistreatedwithfingolimodthespanishgilenyaregistry AT corejaguevara fouryearsafetyandeffectivenessdatafrompatientswithmultiplesclerosistreatedwithfingolimodthespanishgilenyaregistry AT dmunoz fouryearsafetyandeffectivenessdatafrompatientswithmultiplesclerosistreatedwithfingolimodthespanishgilenyaregistry AT jolascoaga fouryearsafetyandeffectivenessdatafrompatientswithmultiplesclerosistreatedwithfingolimodthespanishgilenyaregistry AT apato fouryearsafetyandeffectivenessdatafrompatientswithmultiplesclerosistreatedwithfingolimodthespanishgilenyaregistry AT lramiotorrenta fouryearsafetyandeffectivenessdatafrompatientswithmultiplesclerosistreatedwithfingolimodthespanishgilenyaregistry AT vmecalallana fouryearsafetyandeffectivenessdatafrompatientswithmultiplesclerosistreatedwithfingolimodthespanishgilenyaregistry AT mahernandez fouryearsafetyandeffectivenessdatafrompatientswithmultiplesclerosistreatedwithfingolimodthespanishgilenyaregistry AT memarzo fouryearsafetyandeffectivenessdatafrompatientswithmultiplesclerosistreatedwithfingolimodthespanishgilenyaregistry AT jcalvarezcermeno fouryearsafetyandeffectivenessdatafrompatientswithmultiplesclerosistreatedwithfingolimodthespanishgilenyaregistry AT arodriguezantiguedad fouryearsafetyandeffectivenessdatafrompatientswithmultiplesclerosistreatedwithfingolimodthespanishgilenyaregistry AT xmontalban fouryearsafetyandeffectivenessdatafrompatientswithmultiplesclerosistreatedwithfingolimodthespanishgilenyaregistry AT ofernandez fouryearsafetyandeffectivenessdatafrompatientswithmultiplesclerosistreatedwithfingolimodthespanishgilenyaregistry AT spanishgilenyaregistryinvestigators fouryearsafetyandeffectivenessdatafrompatientswithmultiplesclerosistreatedwithfingolimodthespanishgilenyaregistry |
| _version_ |
1718374208002588672 |